DK2074108T3 - Renin-inhibitorer - Google Patents

Renin-inhibitorer

Info

Publication number
DK2074108T3
DK2074108T3 DK07838381.7T DK07838381T DK2074108T3 DK 2074108 T3 DK2074108 T3 DK 2074108T3 DK 07838381 T DK07838381 T DK 07838381T DK 2074108 T3 DK2074108 T3 DK 2074108T3
Authority
DK
Denmark
Prior art keywords
renin inhibitors
renin
inhibitors
Prior art date
Application number
DK07838381.7T
Other languages
English (en)
Inventor
John J Baldwin
David A Claremon
Colin M Tice
Lawrence W Dillard
Alexey V Ishchenko
Jing Yuan
Zhenrong Xu
Gerard Mcgeehan
Wei Zhao
Robert D Simpson
Suresh B Singh
Patrick T Flaherty
Lanqi Jia
Salvacion Cacatian
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38786973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2074108(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2074108T3 publication Critical patent/DK2074108T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK07838381.7T 2006-09-18 2007-09-18 Renin-inhibitorer DK2074108T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84529106P 2006-09-18 2006-09-18
PCT/US2007/020164 WO2008036247A1 (en) 2006-09-18 2007-09-18 Renin inhibitors

Publications (1)

Publication Number Publication Date
DK2074108T3 true DK2074108T3 (da) 2013-03-11

Family

ID=38786973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07838381.7T DK2074108T3 (da) 2006-09-18 2007-09-18 Renin-inhibitorer

Country Status (23)

Country Link
US (2) US8198453B2 (da)
EP (2) EP2581366A1 (da)
JP (1) JP5331695B2 (da)
KR (1) KR20090064582A (da)
CN (1) CN101528723B (da)
AR (1) AR062797A1 (da)
AU (1) AU2007297729C1 (da)
BR (1) BRPI0718460A2 (da)
CA (1) CA2663263A1 (da)
CL (1) CL2007002689A1 (da)
DK (1) DK2074108T3 (da)
ES (1) ES2400009T7 (da)
HK (1) HK1129115A1 (da)
HR (1) HRP20130144T4 (da)
MX (1) MX2009002740A (da)
NZ (1) NZ575803A (da)
PE (1) PE20080843A1 (da)
PL (1) PL2074108T6 (da)
PT (1) PT2074108E (da)
RS (1) RS52679B (da)
SI (1) SI2074108T1 (da)
TW (1) TWI403510B (da)
WO (1) WO2008036247A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101314277B1 (ko) 2004-10-07 2013-10-02 비타이 파마슈티컬즈, 인코포레이티드 디아미노알칸 아스파르트산 프로테아제 억제제
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
WO2008036216A1 (en) * 2006-09-18 2008-03-27 Vitae Pharmaceuticals, Inc. Piperidine derivatives as renin inhibitors
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
EP2167609A1 (en) * 2007-06-20 2010-03-31 Vitae Pharmaceuticals, Inc. Renin inhibitors
JP2011525488A (ja) * 2008-06-20 2011-09-22 ヴァイティー ファーマシューティカルズ，インコーポレイテッド レニン阻害剤およびその使用方法
EP2306826A4 (en) * 2008-06-26 2011-07-27 Vitae Pharmaceuticals Inc SALTS OF METHYL-2 - ((R)) - (3-CHLOROPHENYL) ((R) 1 - ((S) -2- (METHYLAMINO) -3 ((R) -TETRAHYDRO-2H-PYRAN-3-YL) propylcarbamoyl) piperidin-3-yl) methoxy) ETHYL CARBAMATE
US20100010228A1 (en) * 2008-06-26 2010-01-14 Vitae Pharmaceuticals, Inc. Process for the asymmetric reduction of 3-benzoylpiperidines
AU2016256776B2 (en) * 2009-03-18 2018-04-12 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) * 2009-03-18 2016-08-18 Incarda Therapeutics, Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US8974828B2 (en) 2009-03-18 2015-03-10 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
MX2018009248A (es) 2016-02-01 2019-01-21 Incarda Therapeutics Inc Combinacion de monitoreo electronico con terapia farmacologica inhalada para manejar arritmias cardiacas incluyendo fibrilacion auricular.
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3071618A (en) * 1956-02-02 1963-01-01 Pfizer & Co C Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
US4136163A (en) * 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
JPS5115098A (ja) 1974-07-26 1976-02-06 Asahi Chemical Ind Akurirukeiseniseihinno shorihoho
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4594343A (en) 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
ES2097208T3 (es) 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
DE4018070A1 (de) * 1990-06-06 1991-12-12 Bayer Ag Morpholinoharnstoff-derivate
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
WO1992010491A1 (en) * 1990-12-14 1992-06-25 Merrell Dow Pharmaceuticals Inc. Antiallergic compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
NZ249286A (en) * 1992-02-13 1996-02-27 Merrell Dow Pharma Piperidine-4-ylmethyl thiophene and thiazole derivatives and pharmaceutical compositions
JP4439590B2 (ja) 1992-06-10 2010-03-24 エラン ファーマ インターナショナル，リミティド 表面改質ｎｓａｉｄナノ粒子
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
ES2143058T3 (es) 1994-07-29 2000-05-01 Abbott Lab Procedimiento de preparacion de un 2,5-diamino-3-hidroxihexano sustituido.
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
IL123293A (en) 1995-09-07 2003-06-24 Hoffmann La Roche Piperidine derivatives, their preparation and pharmaceutical compositions containing them
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
WO1998054179A1 (en) 1997-05-29 1998-12-03 Eli Lilly And Company Process for preparing heterocyclic compounds
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
GB9826540D0 (en) * 1998-12-02 1999-01-27 Darwin Discovery Ltd Process
AU2492500A (en) 1999-01-06 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aspartic protease inhibitors, compositions, and associated therapeutic methods
JP2000302757A (ja) 1999-04-16 2000-10-31 Shiseido Co Ltd Ｎ−置換ピペリジン誘導体
CN1416346A (zh) * 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
US6900329B2 (en) * 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
KR20040063110A (ko) 2001-07-11 2004-07-12 엘란 파마슈티칼스, 인크. Ｎ-(3-아미노-2-히드록시-프로필) 치환된 알킬아미드 화합물
MXPA04004428A (es) 2001-11-08 2004-09-10 Elan Pharm Inc Derivados de 2,3-diamino-2-hidroxipropano n,n`-sustituidos.
CN1313472C (zh) 2002-04-26 2007-05-02 吉里德科学公司 Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物
WO2004002483A1 (en) 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
JP2005538177A (ja) 2002-09-10 2005-12-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルツハイマー病処置用置換アミノエーテル化合物
CA2544573A1 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2547551A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
US20060063930A1 (en) 2004-08-20 2006-03-23 Agoston Gregory E Compositions and methods comprising proteinase activated receptor antagonists
KR101314277B1 (ko) * 2004-10-07 2013-10-02 비타이 파마슈티컬즈, 인코포레이티드 디아미노알칸 아스파르트산 프로테아제 억제제
ES2367267T3 (es) * 2005-01-28 2011-10-31 Actelion Pharmaceuticals Ltd. Ciclopropil-(2,3-dimetilbencil)amida del ácido 7-(4-(2-(2,6-dicloro-4-metilfenoxi)etoxi)fenil)-3,9-diazabiciclo(3.3.1)non-6-eno-6-carboxílico como inhibidor de renina para el tratamiento de la hipertensión.
WO2006083924A1 (en) * 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
EP1882684B1 (en) 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
US7872028B2 (en) * 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
WO2008036216A1 (en) 2006-09-18 2008-03-27 Vitae Pharmaceuticals, Inc. Piperidine derivatives as renin inhibitors
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2167609A1 (en) * 2007-06-20 2010-03-31 Vitae Pharmaceuticals, Inc. Renin inhibitors
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
US7773441B2 (en) * 2008-06-18 2010-08-10 Micron Technology, Inc. Memory malfunction prediction system and method
JP2011525488A (ja) 2008-06-20 2011-09-22 ヴァイティー ファーマシューティカルズ，インコーポレイテッド レニン阻害剤およびその使用方法
EP2306826A4 (en) 2008-06-26 2011-07-27 Vitae Pharmaceuticals Inc SALTS OF METHYL-2 - ((R)) - (3-CHLOROPHENYL) ((R) 1 - ((S) -2- (METHYLAMINO) -3 ((R) -TETRAHYDRO-2H-PYRAN-3-YL) propylcarbamoyl) piperidin-3-yl) methoxy) ETHYL CARBAMATE
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo

Also Published As

Publication number Publication date
EP2074108A1 (en) 2009-07-01
EP2581366A1 (en) 2013-04-17
US20090312369A1 (en) 2009-12-17
PE20080843A1 (es) 2008-08-11
ES2400009T3 (es) 2013-04-05
SI2074108T1 (sl) 2013-04-30
PL2074108T3 (pl) 2013-05-31
WO2008036247A1 (en) 2008-03-27
KR20090064582A (ko) 2009-06-19
CN101528723A (zh) 2009-09-09
TW200829574A (en) 2008-07-16
US8198453B2 (en) 2012-06-12
CN101528723B (zh) 2013-04-10
NZ575803A (en) 2011-11-25
US20120225906A1 (en) 2012-09-06
TWI403510B (zh) 2013-08-01
BRPI0718460A2 (pt) 2013-12-03
ES2400009T7 (es) 2013-11-18
EP2074108B1 (en) 2012-11-21
US8580823B2 (en) 2013-11-12
MX2009002740A (es) 2009-06-26
HRP20130144T4 (hr) 2013-10-25
PT2074108E (pt) 2013-03-07
CA2663263A1 (en) 2008-03-27
HRP20130144T1 (en) 2013-03-31
WO2008036247A8 (en) 2008-06-26
AR062797A1 (es) 2008-12-03
PL2074108T6 (pl) 2013-11-29
HK1129115A1 (en) 2009-11-20
JP2010503684A (ja) 2010-02-04
JP5331695B2 (ja) 2013-10-30
AU2007297729A1 (en) 2008-03-27
CL2007002689A1 (es) 2008-04-18
AU2007297729C1 (en) 2012-02-02
RS52679B (en) 2013-06-28
AU2007297729B2 (en) 2011-07-28
EP2074108B3 (en) 2013-06-26

Similar Documents

Publication Publication Date Title
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
CY2017016I2 (el) Αναστολεις πρωτεασωματος
DK2074108T3 (da) Renin-inhibitorer
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
BRPI0719204A2 (pt) Inibidores de hdac
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2402317T3 (da) DGAT-inhibitor
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0814797A2 (pt) Inibidores dna-pk
DK2066662T3 (da) Serinhydrolaseinhibitorer
BRPI0918564A2 (pt) inibidores
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
EP2229363A4 (en) Renin Inhibitors
DE502006004094D1 (de) Bohrfutter
FR2911341B1 (fr) Inhibiteur de corrosion
DE112007003149A5 (de) Spannfutter
DK1991718T3 (da) Korrosionsinhibitorer
BRPI0918966A2 (pt) inibidores de protease
DK1934207T3 (da) Substituerede 4-phenylpiperidiner til anvendelse som renininhibitorer
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
DE602007009087D1 (de) Zerebraler vasospasmus-inhibitor